

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-7. (Canceled)

8. (Currently Amended) A cyclic peptide modulating agent having the formula:



wherein W is the tri-peptide DAE;

wherein  $X_1$  is C and  $X_2$  is  $\overline{EC}$ ; ;

wherein  $Y_1$  and  $Y_2$  are independently selected from the group consisting of amino acid residues, and wherein a covalent bond is formed between residues  $Y_1$  and  $Y_2$ ; and

wherein  $Z_1$  and  $Z_2$  are optional, and if present, are independently selected from the group consisting of amino acid residues and combinations thereof in which the residues are linked by peptide bonds,

and wherein the agent can modulate cadherin-5-mediated endothelial cell adhesion.

9.-104. Canceled

105. (Previously Presented) A modulating agent according to claim 8 linked to a drug.

106. (Previously Presented) A modulating agent according to claim 8 linked to a detectable marker.

107. (Previously Presented) A modulating agent according to claim 8 linked to a targeting agent.

108. (Previously Presented) A modulating agent according to claim 8 linked to a support material.

109. (Original) A modulating agent according to claim 108, wherein the support material is a polymeric matrix.

110. (Original) A modulating agent according to claim 108, wherein the support material is selected from the group consisting of plastic dishes, plastic tubes, sutures, membranes, ultra thin films, bioreactors and microparticles.

111. (Previously Presented) A modulating agent according to claim 8, further comprising one or more of:

(a) a CAR sequence that is specifically recognized by an adhesion molecule other than cadherin-5; and/or

(b) an antibody or antigen-binding fragment thereof that specifically binds to a CAR sequence that is specifically recognized by an adhesion molecule other than cadherin-5.

112. (Original) A modulating agent according to claim 111, wherein the adhesion molecule is selected from the group consisting of cadherins, integrins, occludin, claudins, desmogleins, desmocollins, protocadherins, cadherin-related neuronal receptors, fibronectin, laminin, claudins and other extracellular matrix proteins.

113. (Previously Presented) A composition comprising a modulating agent according to claim 8 in combination with a pharmaceutically acceptable carrier.

114. (Original) A composition according to claim 113, further comprising a drug.

115. (Original) A composition according to claim 113, wherein the modulating agent is present within a sustained-release formulation.

116. (Previously Presented) A pharmaceutical composition according to claim 115, further comprising a modulator of cell adhesion that comprises one or more of:

(a) a CAR sequence that is specifically recognized by an adhesion molecule other than cadherin-5; and/or

(b) an antibody or antigen-binding fragment thereof that specifically binds to a CAR sequence that is specifically recognized by an adhesion molecule other than cadherin-5.

117. (Original) A pharmaceutical composition according to claim 116, wherein the adhesion molecule is selected from the group consisting of cadherins, integrins, occludin, claudins, desmogleins, desmocollins, protocadherins, cadherin-related neuronal receptors, fibronectin, laminin and other extracellular matrix proteins.